Company: Oxford Biomedica
Location: United Kingdom
Drug Type: Gene Therapy
Mechanism Type: Neuroprotection
Mechanism: MoNuDin is a lentiviral vector technology for delivering vascular endothelial growth factor (VEGF) to motor neurons for the treatment of ALS
U.S. Status for ALS: Inactive
 MoNuDin. Oxford BiomMedica, 2016. Accessed 11 Mar 2016 from http://www.oxfordbiomedica.co.uk/monudin-r/.
 VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Azzouz, M et al. Nature. 2004 May 27;429(6990):413-7.
Last updated March 11th, 2016